BioTechnology
Agilent To Present At Jefferies And Goldman Sachs Healthcare Conferences
By Business Wire
Share
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.
Jefferies Global Healthcare Conference
Mike McMullen, Agilent President and CEO
Wednesday, June 7
9:00 – 9:25 a.m. ET / 6:00 – 6:25 a.m. PT
Goldman Sachs 44th Annual Global Healthcare Conference
Bob McMahon, Agilent CFO
Tuesday, June 13
1:00 – 1:40 p.m. ET / 10:00 – 10:40 a.m. PT
Those interested in listening to the live or recorded sessions can access them from the Events section of Agilent’s investor relations website. Recordings will be available for 90 days.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Contacts
Investor Contact:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com
Media Contact:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com
First published on Tue, May 23, 2023
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs' site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.
Tags:
Related News on BioTechnology
Evonetix Closes $24 Million USD (20 Million) Financing
Tue, Feb 7, 2023
By Business Wire
Kane Biotech Strengthens Board With Biotech Executive
Fri, Nov 17, 2023
By GlobeNewswire
Trinity Life Sciences And WhizAI Announce Partnership
Wed, Apr 26, 2023
By Business Wire
Kiromic BioPharma Announces Uplisting To OTCQB Market
Fri, Nov 17, 2023
By Business Wire
Related Events & Webinars on BioTechnology
Trending Business Wire
Jio Expands Video Content Security Relationship With Verimatrix
By Business Wire
Novata Expands Platform To Empower Private Companies With Cutting-Edge Sustainability Solutions
By Business Wire
Schneider Geospatial Acquires Systems Development Group
By Business Wire
TP-Link Introduces Omada Cloud Essentials: A Free And Easy Cloud-Based Management Option For Surveillance Networks And Small Businesses
By Business Wire
Velo3d Welcomes Back Dr. Zach Murphree As Vice President, General Manager To Lead Its Product Development And Customer-First Go-To-Market Strategy
By Business Wire
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion